ABL1 and acute lymphoblastic leukemia: GZD824, also known as olverembatinib, is a multi‐kinase inhibitor previously investigated in clinical trials for chronic myeloid leukaemia and Ph+ acute lymphoblastic leukaemia as a BCR‐ABL inhibitor.